Projects per year
Abstract
Background
A critical step in evaluating healthcare interventions is to understand their impact on healthcare costs. However, there is a limited understanding of the causal impact that biomarkers and risk factors for disease have on healthcare-related costs. Previous studies based on observational data have major limitations including residual confounding and reverse causation. Here, we used a genetically-informed design, Mendelian Randomization (MR), to infer the causal impact of 15 routinely measured and clinically relevant risk factors on annual total healthcare costs.
Methods
We considered 373,160 participants from the FinnGen Study, which were linked to detailed healthcare costs covering inpatient, outpatient, and medication costs. Several MR approaches were used to assess the causal effects of 15 risk factors (e.g., waist circumference (WC), HDL cholesterol, vitamin D), with strong genetic bases on annual total healthcare costs, as well as stratified by service type, age, and sex. We further assessed the generalizability and robustness of our results by accounting for selection bias and by leveraging additional data from 323,774 individuals from the United Kingdom and Netherlands.
Results
Robust causal effects were observed for waist circumference (WC), adult body mass index, and systolic blood pressure, in which a one standard deviation increase in the risk factors corresponded to 22.78% [95% CI: 18.75, 26.95], 13.64% [10.26, 17.12], and 13.08% [8.84, 17.48] increased annual total healthcare costs, respectively. The relative effect of WC on annual total healthcare costs was consistent across age and sex and was not attenuated when accounting for increased risk of five major diseases: back pain, chronic ischemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease, and stroke. A lack of causal effects was observed for some clinically relevant biomarkers, such as albumin, C-reactive protein, and vitamin D.
Conclusion
Our results indicated that increased WC is a major contributor to annual total healthcare costs and more attention should be given to WC screening, surveillance, and mitigation. On the contrary, several biomarkers relevant in clinical settings did not have a direct impact on annual total healthcare costs.
A critical step in evaluating healthcare interventions is to understand their impact on healthcare costs. However, there is a limited understanding of the causal impact that biomarkers and risk factors for disease have on healthcare-related costs. Previous studies based on observational data have major limitations including residual confounding and reverse causation. Here, we used a genetically-informed design, Mendelian Randomization (MR), to infer the causal impact of 15 routinely measured and clinically relevant risk factors on annual total healthcare costs.
Methods
We considered 373,160 participants from the FinnGen Study, which were linked to detailed healthcare costs covering inpatient, outpatient, and medication costs. Several MR approaches were used to assess the causal effects of 15 risk factors (e.g., waist circumference (WC), HDL cholesterol, vitamin D), with strong genetic bases on annual total healthcare costs, as well as stratified by service type, age, and sex. We further assessed the generalizability and robustness of our results by accounting for selection bias and by leveraging additional data from 323,774 individuals from the United Kingdom and Netherlands.
Results
Robust causal effects were observed for waist circumference (WC), adult body mass index, and systolic blood pressure, in which a one standard deviation increase in the risk factors corresponded to 22.78% [95% CI: 18.75, 26.95], 13.64% [10.26, 17.12], and 13.08% [8.84, 17.48] increased annual total healthcare costs, respectively. The relative effect of WC on annual total healthcare costs was consistent across age and sex and was not attenuated when accounting for increased risk of five major diseases: back pain, chronic ischemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease, and stroke. A lack of causal effects was observed for some clinically relevant biomarkers, such as albumin, C-reactive protein, and vitamin D.
Conclusion
Our results indicated that increased WC is a major contributor to annual total healthcare costs and more attention should be given to WC screening, surveillance, and mitigation. On the contrary, several biomarkers relevant in clinical settings did not have a direct impact on annual total healthcare costs.
Original language | English |
---|---|
Article number | 5672 |
Journal | Nature Communications |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - 13 Sept 2023 |
Bibliographical note
Funding Information:We would like to acknowledge Camiel M. van der Laan and Dorret I. Boomsma for their contribution of healthcare costs summary statistics from the Netherlands Twin Register, as well as Bart Ferket for his insights on health economics in designing this study. We would also like to acknowledge all of the study participants for their generous participation in FinnGen and other biobanks, as well as FinnGen as a study group that has contributed to this study. A.G. was supported by the Academy of Finland (grant no. 323116) and by the European Research Council under the European Union’s Horizon 2020 Research and Innovation Programme (grant no. 945733). This project has also received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement no. 101016775. The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_00011/1]. NMD was supported via a Norwegian Research Council grant number 295989.
Funding Information:
A.G. was supported by the Academy of Finland (grant no. 323116) and by the European Research Council under the European Union’s Horizon 2020 Research and Innovation Programme (grant no. 945733). This project has also received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement no. 101016775. The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_00011/1]. NMD was supported via a Norwegian Research Council grant number 295989.
Publisher Copyright:
© 2023, Springer Nature Limited.
Research Groups and Themes
- Bristol Population Health Science Institute
Fingerprint
Dive into the research topics of 'Quantifying the causal impact of biological risk factors on healthcare costs'. Together they form a unique fingerprint.Projects
- 1 Finished
-
IEU: MRC Integrative Epidemiology Unit Quinquennial renewal
Gaunt, L. F. (Principal Investigator) & Davey Smith, G. (Principal Investigator)
1/04/18 → 31/03/23
Project: Research